U.K. Rare Diseases Treatment Market Size & Outlook
The rare diseases treatment market in the UK is expected to reach a projected revenue of US$ 14,771.1 million by 2033. A compound annual growth rate of 10.9% is expected of the UK rare diseases treatment market from 2026 to 2033.
- Pharmaceuticals
- Rare or Orphan Diseases Treatment
- rare diseases treatment market report
- Rare or Orphan Diseases Treatment
Revenue, 2025 (US$M)
$6,385.5
Estimate, 2026 (US$M)
$7,173.4
Forecast, 2033 (US$M)
$14,771.1
CAGR, 2026 - 2033
10.9%
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the rare diseases treatment market report market
Every figure cited from GVR research
UK rare diseases treatment market highlights
- The UK rare diseases treatment market generated a revenue of USD 6,385.5 million in 2025 and is expected to reach USD 14,771.1 million by 2033.
- The UK market is expected to grow at a CAGR of 10.9% from 2026 to 2033.
- In terms of segment, cancer was the largest revenue generating therapeutic area in 2025.
- Musculoskeletal Conditions is the most lucrative therapeutic area segment registering the fastest growth during the forecast period.
Rare diseases treatment market data book summary
| Market revenue in 2025 | USD 6,385.5 million |
| Market revenue in 2033 | USD 14,771.1 million |
| Growth rate | 10.9% (CAGR from 2026 to 2033) |
| Largest segment | Cancer |
| Fastest growing segment | Musculoskeletal Conditions |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cancer, Neurological Conditions, Cardiovascular Conditions, Musculoskeletal Conditions, Hematologic Disorders, Infectious Diseases, Metabolic Disorders, Endocrine Disorders |
| Key market players worldwide | Roche Holding AG, Pfizer Inc, PTC Therapeutics Inc, AstraZeneca PLC, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Bayer AG, AbbVie Inc, Merck & Co Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, UK accounted for 3.0% of the global rare diseases treatment market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany rare diseases treatment market is projected to lead the regional market in terms of revenue in 2033.
- France is the fastest growing regional market in Europe and is projected to reach USD 12,450.4 million by 2033.
No credit card required*
Publish Date: Jun 24, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rare Diseases Treatment Market Report
Rare diseases treatment market report segmentation & scope
Others
Rare Diseases Treatment Market Report Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
| PTC Therapeutics Inc | View profile | 995 | 100 Corporate Court, South Plainfield, NJ, United States, 07080 | www.ptcbio.com |
U.K. rare diseases treatment market report
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Rare Diseases Treatment Market Outlook will help companies and investors design strategic landscapes.
Cancer was the largest segment with a revenue share of 31.55% in 2025.
Horizon Databook has segmented the U.K. rare diseases treatment market based on cancer, neurological conditions, cardiovascular conditions, musculoskeletal conditions, hematologic disorders, infectious diseases, metabolic disorders, endocrine disorders covering the revenue growth of each sub-segment from 2021 to 2033.
- U.K. Rare Diseases Treatment Market Therapeutic Area Outlook (Revenue, USD Million , 2021-2033)
- Cancer
- Neurological Conditions
- Cardiovascular Conditions
- Musculoskeletal Conditions
- Hematologic Disorders
- Infectious Diseases
- Metabolic Disorders
- Endocrine Disorders
- Others
- U.K. Rare Diseases Treatment Market Drug Outlook (Revenue, USD Million , 2021-2033)
- Biologics
- Biosimilar
- Small molecules
- U.K. Rare Diseases Treatment Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Injectable
- Others
- U.K. Rare Diseases Treatment Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
Reasons to subscribe to rare diseases treatment market report databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of rare diseases treatment market report databook
- Our clientele includes a mix of rare diseases treatment market report companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. rare diseases treatment market report, including forecasts for subscribers. This country databook contains high-level insights into U.K. rare diseases treatment market report from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.K. Rare Diseases Treatment Market, 2021-2033 (US$M)
UK Therapeutic Area - Rare Diseases Treatment Market Statistics, 2025 - 2033 (US$M)
